These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 17706566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T, Härtter S, Burger E.
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D.
    Lancet; 2004 Apr 10; 363(9416):1179-83. PubMed ID: 15081648
    [Abstract] [Full Text] [Related]

  • 9. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F, Garbe E.
    Mov Disord; 2009 Jan 15; 24(1):129-33. PubMed ID: 19170199
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Cardiac valvulopathy and dopamine agonist].
    Grandas F.
    Neurologia; 2007 Dec 15; 22(10):870-81. PubMed ID: 17671852
    [Abstract] [Full Text] [Related]

  • 16. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
    Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Morikawa K, Nakayama T.
    Intern Med; 2011 Dec 15; 50(7):687-94. PubMed ID: 21467699
    [Abstract] [Full Text] [Related]

  • 17. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB, Reimold SC, O'Suilleabhain PE.
    Arch Neurol; 2007 Mar 15; 64(3):377-80. PubMed ID: 17353380
    [Abstract] [Full Text] [Related]

  • 18. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.
    J Clin Endocrinol Metab; 2008 Sep 15; 93(9):3348-56. PubMed ID: 18559921
    [Abstract] [Full Text] [Related]

  • 19. Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells.
    Oana F, Onozuka H, Tsuchioka A, Suzuki T, Tanaka N, Kaidoh K, Hoyano Y, Hiratochi M, Kikuchi S, Takehana Y, Shibata N.
    J Heart Valve Dis; 2014 Mar 15; 23(2):246-52. PubMed ID: 25076559
    [Abstract] [Full Text] [Related]

  • 20. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J, Ulmanová O, Růzicka E.
    Cas Lek Cesk; 2005 Mar 15; 144(2):123-6. PubMed ID: 15807300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.